These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 7663659

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Recombinant human deoxyribonuclease for cystic fibrosis.
    Jones AP, Wallis CE.
    Cochrane Database Syst Rev; 2003; (3):CD001127. PubMed ID: 12917899
    [Abstract] [Full Text] [Related]

  • 27. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM, Volpi S, Salonini E, Müllinger B, Kroneberg P, Bakker M, Hop WC, Assael BM, Tiddens HA.
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [Abstract] [Full Text] [Related]

  • 28. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K, Hamilton S, Johnson C.
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME.
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Intervention Trial Study Group.
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [New pharmacological approaches: rhDNase].
    Tournier G, Sardet A, Grosskopf C, Baculard A, Delaisi B.
    Rev Pneumol Clin; 1995 Dec; 51(3):193-200. PubMed ID: 7569583
    [Abstract] [Full Text] [Related]

  • 38. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
    Suri R, Metcalfe C, Wallis C, Bush A.
    Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
    [Abstract] [Full Text] [Related]

  • 39. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.
    Oster G, Huse DM, Lacey MJ, Regan MM, Fuchs HJ.
    Ann Pharmacother; 1995 May; 29(5):459-64. PubMed ID: 7655127
    [Abstract] [Full Text] [Related]

  • 40. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
    Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK.
    Am J Respir Crit Care Med; 2002 Aug 01; 166(3):352-5. PubMed ID: 12153969
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.